Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198276 · ClinicalTrials.gov registry record · Phase 4
Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer
A Phase 4 study of Cancer, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 88
- Enrollment target
- 1
- Study location
NCT00198276 is a Phase 4 study of Cancer that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 88 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00198276, a Phase 4 study of Cancer, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 88 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to study the safety and efficacy of MedPulser Electroporation with bleomycin treatment of cutaneous and subcutaneous foci of cancer.
Conditions Studied
Interventions
- COMBINATION_PRODUCT MedPulser Electroporation with bleomycin
Study Locations (1)
California
- Inovio Biomedical Corporation - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2004-02 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198276
The ClinicalTrials.gov registry entry for NCT00198276 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which MedPulser Electroporation with bleomycin is the first listed.
NCT00198276 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00198276 about?
NCT00198276 is a clinical study titled "Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer". The purpose of the study is to study the safety and efficacy of MedPulser Electroporation with bleomycin treatment of cutaneous and subcutaneous foci of cancer.
What is the current status of trial NCT00198276?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 88 participants. The study started on 2004-02. Estimated completion is 2008-09.
What conditions does trial NCT00198276 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT00198276?
The interventions under investigation include: MedPulser Electroporation with bleomycin (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT00198276?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00198276 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
COMPLETED · Phase 4
-
Tobacco Treatment Comparison for Cancer Care
COMPLETED · Phase 4
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.